The studies employed randomized, double-blind, placebo-controlled designs except Li (2017) conducted a case-control study comparing patients with IBS-C to a control group without IBS-C
Phase 3 trials extended to 68 weeks confirmed continued weight loss (28.7% at 68 weeks vs 24.2% at 48 weeks on the 12mg dose)
Activation of these receptors is associated with enhanced endothelial function, improved myocardial glucose uptake, reduced oxidative stress, and modulation of atherosclerotic plaque biology
Research Reference Only Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only
Track strength, energy and recovery as functional markers that often change earlier than the scale
This same principle applies to other next-generation metabolic peptides like Survodutide and Mazdutide